Cat. No.: X23-10-ZQ358
JAK inhibitor Baricitinib, Purity ≥98%
Synonym: Baricitinib; 1187594-09-7; Olumiant; INCB028050; LY3009104; INCB 028050; 2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; JAK inhibitor
- MDL: MFCD21608464
- CAS Number: 1187594-09-7
- Compound CID: 44205240
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Properties
Description
Baricitinib, soluble in DMSO and insoluble in ethanol and water, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, TYK2, c-Met, Chk2, JAK2, and JAK3.
Molecular Formula
C16H17N7O2S
Targets
JAK1: 5.9 nM; TYK2: 53 nM; c-Met: >10 μM; Chk2: >1 μM; JAK2: 5.7 nM; JAK3: >400 nM
Solubility
DMSO: 65 mg/mL (175 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
Baricitinib is used in research to evaluate its effectiveness as a JAK1 and JAK2 inhibitor for treating rheumatoid arthritis and other inflammatory diseases.
Related Products
-
JAK inhibitor JAK/HDAC-IN-1, Purity ≥98%
-
JAK inhibitor 1,2,3,4,5,6-Hexabromocyclohexane, Purity ≥98%
-
JAK inhibitor Abrocitinib, Purity ≥98%
-
JAK inhibitor AZ-3, Purity ≥98%
-
JAK inhibitor AZ-960, Purity ≥98%
-
JAK inhibitor AZD1480, Purity ≥98%
Quick Links